Iluvien for chronic DME to be fully reimbursed in France

The Transparency Commission of the French National Health Authority issued a positive opinion regarding the reimbursement and hospital listing of Iluvien by the French National Health Insurance, according to a news release.Under the Affection de Longue Duree program for severe chronic diseases, patients in France will be fully reimbursed for the cost of Iluvien (sustained-release fluocinolone acetonide, Alimera Sciences) for the treatment of chronic diabetic macular edema that is unresponsive to available therapies.

Full Story →